CME Information
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by educational grants from AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc.
Target Audience
The intended audience for this activity is gastroenterologists, pharmacists, and other health care professionals involved in the management of patients with inflammatory bowel disease (IBD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Incorporate the latest American College of Gastroenterology guidelines in daily practice.
- Apply appropriate criteria for determining the severity of ulcerative colitis (UC).
- Consider patient-reported outcomes when making treatment decisions.
- Initiate steps to ensure appropriate management of CD patients during the COVID-19 pandemic.
- Incorporate shared decision-making into clinical practice.
Activity Chair
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, PA
Faculty
Maria T. Abreu, MD
Director, Crohn's and Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Miami, FL
Chair, International Organization For the Study of Inflammatory Bowel Disease
Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Aline Charabaty, MD, AGAF, FACG
Assistant Clinical Director of the Division of Gastroenterology
Johns Hopkins School of Medicine
Director of IBD Center
Sibley Memorial Hospital | John Hopkins Medicine
Washington, DC
Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL
Millie D. Long, MD, MPH
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Patient Advocate
Jessica Caron, MS
Founder, Chronically-Jess.com
Goffstown, NH
Reviewers
Shubha Bhat, PharmD, MS, BCACP
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is acceptable for 2.0 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-030-H01-P, effective 11/30/2021. This is a knowledge-based activity and there is no fee to attend.
This enduring material is approved for 1 year from the date of original release, November 30, 2021 to November 29, 2022.
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 9 of the 12 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.
Pharmacist learners who submit their NABP ID and DOB will be reported directly to the ACPE through CPE Monitor within 30 days.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.
Activity Chair and Faculty report the following relationship(s)
Maria T. Abreu, MD
Consulting Fee: AbbVie, Alimentiv, Arena, Bellatrix, Bristol-Myers Squibb, Cosmo Biopharma, Eli Lilly, Gilead, Intellisphere, Janssen, Prometheus
Speakers Bureau: Alimentiv, Arena, Intellisphere, Janssen, Takeda
Contracted Research: AbbVie, Genentech, Pfizer, Prometheus, Takeda
Jessica R. Allegretti, MD, MPH
Consulting Fee: Artugen, Bacainn, Bristol Myers Squibb, Finch Therapeutics, Iterative Scopes, Janssen, Morphic, Pandion, Pfizer, Servatus
Contracted Research: Artugen, Janssen, Merck, Pfizer
Aline Charabaty, MD, AGAF, FACG
Consulting Fee: AbbVie, Bristol-Myers Squibb, Janssen, Pfizer, Takeda
Stephen B. Hanauer, MD
Consulting Fee: AbbVie, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres, Takeda, TiGenix, UCB, VHsquared
Contracted Research: AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB
Speakers Bureau: AbbVie, American Recent, Bristol-Myers Squibb, Janssen, Pfizer, Takeda
Gary R. Lichtenstein, MD
Royalty: Professional Communications, Inc.; SLACK Incorporated
Consulting Fee: AbbVie, American Regent, Bristol-Myers Squibb, Celgene, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, MedEd Consultants, Merck, Morphic Therapeutics, Prometheus, Romark, Salix/Valeant, Sandoz, Shire, UCB
Contracted Research: Bristol-Myers Squibb, Celgene, UCB
Ownership Interest: Virgo
Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
Data and Safety Monitoring Board: Eli Lilly
Author Honoraria: UpToDate
Editor Honoraria: American College of Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
Millie D. Long, MD, MPH
Consulting Fee: AbbVie, Bristol-Myers Squibb, Calibr, Genentech, Janssen, Lilly, Pfizer, Prometheus, Roche, Salix, Takeda, Target PharmaSolutions, Theravance, Valeant
Contracted Research: Pfizer, Takeda
David T. Rubin, MD
Consulting Fee: AbbVie, AltruBio, Allergan, Arena, Athos, Bellatrix, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Connect Biopharma, Galen/Atlantica, Genentech/Roche, Gilead, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen, Lilly, Materia Prima, Pfizer, Prometheus, Reistone, Takeda, Techlab
Contracted Research: Takeda
Patient Advocate reports the following relationship(s)
Jessica Caron, MS
No relevant financial relationships to disclose.
Reviewers reports the following relationship(s)
Shubha Bhat, PharmD, MS, BCACP
No relevant financial relationships to disclose.
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com